Did you know that your browser is out of date?
For the best experience we recommend upgrading to the latest version of these supported browsers:
I wish to continue viewing on my unsupported browser
For the best experience we recommend upgrading to the latest version of these supported browsers:
I wish to continue viewing on my unsupported browser
03 April 1995
By Dr. Thomas McCarthy with Dr. Scott Thomas
Analyzing damages in health care antitrust cases involves many of the same elements as analyzing damages in other antitrust and complex commercial cases. However, the institutional differences and the complexities created by heterogenous products, differential pricing, and the agency relationship among patients, physicians, and third party payors can affect how these markets function. In this white paper, the authors argue that analyzing damages in health care antitrust cases must be regarded as a case-by-case issue requiring careful attention to the way in which competition has been harmed, if at all, and how this harm translates to injured buyers or competitors.